Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
PMID: 20462946
2010
The Journal of antimicrobial chemotherapy
Table: V106A
Discussion: For example, nevirapine selects for V106A, Y181C/I/V and G190A significantly more frequently than efavirenz, whereas efavirenz preferentially selects for L100I, K101P, V106M, Y188L, G190S and P225H.
Discussion: The following nine pairs were still significantly correlated in our analysis: Y181C/G190A, K101E/G190A, Y181C/H221Y, V108I/
Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.
PMID: 20535242
2010
Letters in drug design & discovery
Introduction: (1)) retains activity against HIV-1 containing the single key NNRTI mutations K103N, V106A or L100I.
Introduction: Mutations associated with resistance to NNRTIs include L100I, K101E, K103N, V106A, V108I, V179D, Y181C, Y188C/L/H, G190A/E/S, M230L, P236L and Y318F.
Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.
Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
Abstract: K103N and Y181C mutants had normal RNase H activity; V106A, G190A, and G190S mutants had moderate reductions in activity; and the P236L mutant had substantially reduced activity.
Abstract: K103N and Y181C viruses had fitness similar to that of the wild type while V106A, G190A, G190S, and P236L viruses had reduced fitness.
Abstract: We measured the fitness of six NNRTI-resistant mutants, the K103N, V106A, Y181C
Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.
Abstract: Here, we employ stochastic simulations and a mathematical model to estimate the frequencies of strains carrying different combinations of the common nevirapine resistance mutations K103N, V106A, Y181C, Y188C, and G190A in chronically infected HIV-1 patients naive to nevirapine.
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Method: NVP-R was defined by mutations present at the following amino acid sites: L100I, K101E/P, K103N/S, V106A/M, V108I, Y181C/I/V, Y188C/L/H, or G190A/S/E based on recommendations from International AIDS Society-USA Drug Resistance Mutations and Stanford University drug-resistance database.
Table: V106A/M
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
Abstract: These included V90I, A98G, L100I, K1O1E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F
Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients.
Result: Among these isolates, 6 contained the known RTI-associated resistant mutations, D67N (n=2), K238S (n=2) (http://www.hiv.lanl.gov/content/index), V108I/K238S (n=1) and V106A/V108I/K238S (n=1), and thus were excluded from further analysis.
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
PMID: 19552593
2009
AIDS research and human retroviruses
Introduction: Thirty-six (45.0%) of the 80 infants had at least one NVP resistance mutation detected; the mutations identified were Y181C (n = 28), K103N (n = 9), Y188C (n = 3), G190A (n = 30), V106A (n = 2), V106M (n = 2), and K101E (n = 1); 10 infants had two or more NVP resistance mutations detected.
HIV mutation literature information.
PMID: 
2010
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT